VBI Vaccines Inc.

VBI Vaccines — Investor Presentation (May 2018)

11 slides from VBI Vaccines's investor presentation, May 10, 2018

  1. Slide 1: VBI Vaccines: Final Phase I Results

    {3 VBI VACCINES FINAL PHASE | Pell NASDAQ: VBIV " MAY 10 2018

  2. Slide 2: Cautionary Statement Regarding Forward-Looking Information

    Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 an

  3. Slide 3: What is CMV?

    ——————— What is CMV? CYTOMEGALOVIRUS (CMV) IS A COMMON VIRUS THAT INFECTS ONE IN EVERY TWO PEOPLE IN MANY DEVELOPED COUNTRIES * Most CMV infections are “silent” — most people who are infected with CMV exhibit no signs or symptoms * However, CMV can cause serious disease in newborns when a woman is i

  4. Slide 4: Congenital CMV Disease Burden

    ——————— Congenital CMV Disease Burden = Each year, approximately 30,000 infants are born with CMV infection, of which more than 5,000 U.S. infants will develop permanent problems = Inthe U.S., the direct economic costs of CMV infection exceeds $3.0B annually U.S. CHILDREN BORN WITH OR DEVELOPING LON

  5. Slide 5: CMV Phase I Clinical Study Design

    ——————— CMV Phase | Clinical Study Design Enrolled Population: 128 CMV-Negative Healthy Adults (18-40 yrs) Design: Observer-blind five arm study, subjects randomized in a 1:1:1:1 ratio to receive vaccination at month 0, 2, and 6 of either: + 0.5 of gB-G content with alum (VBI-1501A 0.5yg) + 1.0ug of

  6. Slide 6: gB Antibody Binding Titers - Kinetics

    ——————— gB Antibody Binding Titers - Kinetics ‘vb Anti-gB Endpoint Titer (1/X) © VBI-1501A (2ug gB) & VBI-1501A (1g gB) > VBI-1501A (0.549 gB) = VBI-1501 (pg) 10 10 10 0 28 56 84 112 140 168 196 224 252 280 308 336 Days t t t Vaccine immunizations NASDAQ; VBIV 6

  7. Slide 7: Fibroblast Cell nAb Seroconversion Rate

    Fibroblast Cell nAb Seroconversion Rate 100% nAb response 1 month after 3 2yg dose of VBI-1501A CMV" Healthy Subjects Hl VBI-1501A (2pg gB) i VBE-1501A (tug 98) \VBI-1501A (0.5ug 9B) 30% — 2) VBI-1501 (14g 9B) Fibroblast nAb Seroconversion (%) + The GMT for CMV* sera was 237 (Cl: 140,400) and for th

  8. Slide 8: Correlation Between gB Binding Titers & nAb Activity

    ——————— Correlation Between gB Binding Titers & nAb Activity + The highest dose of VBI-1501A (2g) demonstrated a 31% neutralizing antibody seroconversion rate after three vaccinations, up from 17% after two vaccinations * The epithelial cell neutralizing activity was associated with higher binding t

  9. Slide 9: Summary of Final Phase I Study Results

    ——————— Summary of Final Phase | Study Results * VBI-1501A is safe and well tolerated at all doses tested, with no concern about evaluating VBI-1501A at higher doses + VBI-1501A is immunogenic, even at a low dose © gB antibody binding titers induced at all dose levels, with clear evidence of dose- d

  10. Slide 10: Clinical Milestones by Program

    ——————— Clinical Milestones by Program MN BE vei-1501A : Congenital cmv * H2 2018 : Regulatory discussions to determine next stage of clinical development TN HI sci-B-vace : Hepatitis B Y April 2018 : Completion of enrollment in PROTECT study * Q2 2018 : Expected completion of enrollment in CONSTANT

  11. Slide 11: win

    win ES ° V | = = S G 7M) Myyii\ VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 [email protected]

VBI Vaccines — Investor Presentation (May 2018) on 6ix